FIELD: biotechnology.
SUBSTANCE: humanized antibody against SIRPα or an antigen-binding fragment thereof are proposed. A nucleic acid molecule encoding the antibody and a host cell for producing the antibody containing said nucleic acid molecule are also proposed. The invention also relates to the use of humanized antibodies against SIRPα in treatment of solid tumours and hematologic malignancies in humans, optionally in combination with additional anticancer therapeutic agents.
EFFECT: invention can be used in anticancer therapy.
21 cl, 14 dwg, 17 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-CD47 ANTIBODIES AND METHODS FOR USE THEREOF | 2013 |
|
RU2693078C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| METHOD OF MODIFICATION OF POLYPEPTIDE FOR PURIFICATION OF POLYPEPTIDE MULTIMERS | 2010 |
|
RU2606264C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
